cc-5013
CCND1 Positive
M.D. Anderson Cancer CenterPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the CCND1 Positive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Obinutuzumab Emory University | Phase 2 | CCC |
Zofran Emory University | Phase 2 | CCC |
Ibrutinib M.D. Anderson Cancer Center | Phase 2 | CCC |
DEXAMETHASONE M.D. Anderson Cancer Center | Phase 2 | CCC |
Venetoclax Emory University | Phase 2 | CCC |
Bendamustine Emory University | Phase 2 | CCC |
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER M.D. Anderson Cancer Center | Phase 2 | CCC |
Same molecule, other indications
cc-5013 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →